Development and Evaluation of a Rapid Diagnostic Test for *Plasmodium falciparum*, *P. vivax*, and Mixed-Species Malaria Antigens

Gyu-Cheol Lee, Eun-Sung Jeon, Dung Tien Le, Tong-Soo Kim, Jong-Ha Yoo, Hak Yong Kim, and Chom-Kyu Chong*

Water Analysis and Research Center, K-Water, Daejeon, Republic of Korea; Institute of BioMedicals, Bioland Ltd., Cheongwon, Chungbuk, Republic of Korea; Research Team for Vector-borne Diseases, National Agriculture Research Center, Ibaraki, Japan; Department of Parasitology, School of Medicine, Inha University, Incheon, Republic of Korea; Department of Laboratory Medicine, National Health Insurance Corporation Ilsan Hospital, Goyang, Gyeonggi, Republic of Korea; Department of Biochemistry, College of Natural Sciences, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea

Abstract. *Plasmodium falciparum* and *P. vivax* malaria are endemic to many parts of the world and humans can be co-infected with both species. Because each *Plasmodium* species has different biological and clinical characteristics, accurate differentiation of the infecting species is essential for effective treatment. Therefore, we produced three monoclonal antibodies that recognize the lactate dehydrogenase of *P. falciparum*, *P. vivax*, or both to develop the first *P. falciparum*, *P. vivax*, and mixed-species infections malaria antigen detection kit. The detection limits of this kit were 150 and 250 parasites/µL for *P. falciparum* and *P. vivax*, respectively, and the kit was able to detect mixed-species infections. The sensitivity and specificity of this kit was assessed with 722 clinical specimens. Our results showed that its sensitivities for *P. falciparum*, *P. vivax*, and mixed-species infection were 96.5%, 95.3%, and 85.7%, respectively. In addition, its specificity was high (99.4%).

INTRODUCTION

Malaria is a severe human health problem in many parts of the world. It is caused by one or more infections with *Plasmodium falciparum*, *P. vivax*, *P. malariae*, and *P. ovale*. Among these parasites, *P. falciparum* and *P. vivax* are the most widespread and common causes of mixed-species malaria, which is defined as co-infection with more than one species or genotype of *Plasmodium*. Clinical diagnosis of mixed-species malaria is difficult because the ability of existing assays to identify and differentiate the mixed-species infections is limited. As a result, mixed-species malaria infections are often not properly diagnosed and their prevalence is underestimated. Therefore, mistreatment of a single species, rather than multiple species, can have serious clinical consequences. Therapeutic studies have demonstrated a high prevalence (up to 30%) of infection with other malaria species during convalescence, which suggests co-infection.

The diagnosis of mixed-species malaria is critical for therapeutic decisions, including the selection, dose, and timing of anti-malarial drugs. Mistreatment of a single species, rather than multiple species, can have serious clinical consequences. For example, Boyd and Kitchen reported that *P. falciparum* can suppress *P. vivax* parasitaemia in patients, which is known as interspecies inhibition. Likewise, Mason and McKenzie predicted that when mixed-species malaria is misdiagnosed as a single species *P. vivax* infection, treatment of *P. vivax* may increase *P. falciparum* parasitaemia. Many clinical studies have found high rates of *P. vivax* infection after treatment of single-species *P. falciparum* infection. In addition, mixed-species infections are related to the growing problem of anti-malarial drug resistance, which can enable emergence of a drug-resistant population of *Plasmodium* parasites and relapse infection.

Microscopy and polymerase chain reaction have been the diagnostic methods of choice for malaria, including identification of species and detection of mixed-species infections. However, these methods have several limitations, including expertise and time, which make them unfavorable for point-of-care testing. As a result, several rapid diagnostic tests (RDTs) have been developed to simplify point-of-care testing for malaria. The target antigens in these tests are usually histidine-rich protein-II (HRP-II), *Plasmodium* lactate dehydrogenase (pLDH), and *Plasmodium* aldolase. Although commercially available RDTs are able to differentiate *P. falciparum* from non-*P. falciparum* infections, they are not able to differentiate non-*P. falciparum* species or identify mixed-species infections. We report the development and evaluation of the first RDT, known as the *P. falciparum*, *P. vivax*, and mixed-species infections malaria antigen (FVM Ag) detection kit, which can identify both single-species *P. falciparum* or *P. vivax* infections and mixed infections with these two species.

MATERIALS AND METHODS

Protein expression and purification. Recombinant *P. falciparum* and *P. vivax* LDH (PfLDH and PvLDH, respectively) were expressed in *Escherichia coli*, and then purified by using diethylaminoethyl ion exchange chromatography, followed by Blue Sepharose column chromatography. Briefly, bacterial strains of *E. coli* BL21(DE3) cells were transformed with the pET-15b expression vector (Novagen, Merck, Darmstadt, Germany) that contained the genes for PfLDH and PvLDH. The transformants were grown at 37°C in Luria-Bertani medium to an optical density at 600 nm (optical density at 600 nm [OD600]) of 0.7–0.8. Protein expression was induced with 0.5 mM isopropyl-β-d-thiogalactoside for 4 hours at 30°C, and cells were then harvested by centrifugation at 5,000 × g for 20 minutes. The cell pellets were resuspended in a standard buffer of 50 mM Tris-HCl, pH 7.5, 10 mM EDTA, and 1 mM phenylmethylsulfonyl fluoride and lysed by sonication. Subsequently, the homogenate was centrifuged at 20,000 × g for 20 minutes, and the supernatant then was applied to a diethylaminoethyl ion exchange column. The unbound proteins were loaded onto a Blue Sepharose column (GE Healthcare, Piscataway, NJ) that was equilibrated with the standard buffer. After washing the unbound proteins off with the standard buffer, the protein fractions were collected and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
buffer, the bound proteins were eluted with the elution buffer (standard buffer plus 10 mM nicotinamide adenine dinucleotide). Proteins in the eluent were identified by using sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis,23 and quantified by using the Bradford method.22 The purified proteins were used as immunogens and antigens in the hybridoma screening.

Preparation of polyclonal antibodies. Goat anti-mouse IgG was produced by immunizing goats with mouse IgG, and then purified by using affinity chromatography with protein G Sepharose (Thermo Fisher Scientific, Waltham, MA). Goat anti-mouse IgG was used to capture antibodies on the control line of the RDT.

Preparation of monoclonal antibodies. Recombinant Pf/LDH and Pf/LDH were used to immunize seven-week-old female BALB/c mice. The recombinant proteins were mixed with complete Freund’s adjuvant for the first immunization and with incomplete Freund’s adjuvant for the second and third immunizations. The immunizations were conducted at two-week intervals. The titer of antibodies against Pf/LDH was monitored by using an enzyme-linked immunosorbent assay in a multiwell plate coated with 2 mg/mL of Pf/LDH. When the OD540 of a 1,000-fold dilution of blood was greater than 0.2, the next booster immunization step was performed. The booster immunization was performed by injecting 0.2 mL of a solution of Pf/LDH into the tail vein. Three days after the final booster immunization, mouse spleen cells were fused with Sp2/0 myeloma cells. The resulting hybridomas were produced as described.23

Hybridomas that produced positive antibodies in the screening were selected for single-cell subcloning by using the limited dilution method. The hybridomas were then used to produce ascitic fluid in the mice. IgG was purified by using protein G Sepharose. The cloned monoclonal antibodies (mAbs) were isotyped by using the Mouse Monoclonal Antibody Isotyping Kit (Sigma-Aldrich, St. Louis, MO).

Preparation of colloidal gold–conjugated monoclonal antibodies. Colloidal gold particles (mean diameter = 40 nm) were prepared according to the method of Frens.24 Briefly, 100 mL of 0.01% HAuCl4 was boiled. A total of 1.8 mL of 1% trisodium citrate solution was then added while constantly stirring the solution. After the color of the solution changed to wine-red for approximately 45 seconds, the solution was boiled for 5 minutes and cooled and stirred for 10 minutes. The colloidal gold solution was stored in a dark bottle at 4°C and used to prepare colloidal gold-conjugated mAb.

Monoclonal antibody against pLDH was conjugated with colloidal gold particles as described.25–27 Briefly, mAbs were dialyzed against phosphate-buffered saline for three hours at 4°C. The gold solution was added to pH 9.0 with 0.2 M K2CO3, and then mixed with the mAb (1 mg of mAb/100 mL of gold solution; OD540 = 2). The resulting mixture was incubated for 30 minutes at room temperature. Subsequently, the gold conjugate was blocked with 1% bovine serum albumin for 30 minutes under the same conditions. Finally, the gold conjugate was washed three times with phosphate-buffered saline containing 1% bovine serum albumin and the absorbance was measured at 450 nm.

Preparation of the RDT for malaria. The FVM Ag RDT was prepared as follows. First, 1.0 mg/mL of goat anti-mouse IgG, 1.0 mg/mL of mAb against Pf/LDH (clone 2E11), and 1.2 mg/mL of mAb against Pf/LDH (clone 1H3) were immobilized on the control line (C), test line 1 (T1), and test line 2 (T2), respectively, of the nitrocellulose membrane. The membrane was then dried for one day at room temperature at a relative humidity of less than 20%. The colloidal gold–conjugated mAb (clone 8C10) was dried on a glass fiber and used as the conjugate pad. The sample pad was prepared by treating cellulose paper with 0.1 M Tris-Cl, pH 8.0, containing 0.5% polyvinyl alcohol and 0.5% Tween-20. The absorbance pad consisted of untreated cellulose paper. All pads overlapped partially to ensure continuous migration of the sample solution along the test strip.

Assay procedure and interpretation of FVM Ag rapid diagnostic test result for malaria. The assay procedure of the FVM Ag RDT is shown in Figure 1A. Briefly, the test is started by loading 5 μL of a blood sample onto the hemolysis pad, and then dispensing 4 drops (approximately 100 μL) of 0.1 M Tris-Cl buffer, pH 8.0, containing 0.1% casein and 1% Tween-20 onto the sample pad. The results can be interpreted approximately 15–20 minutes later. The control line should appear in all tests. If a red band appears at T1, the sample is P. falciparum-positive infection. If a band appears at T2, the sample is P. vivax-positive infection. If there are bands at both T1 and T2, then the sample is a mixed-species (Pf+/Pv+) infection (Figure 1B).

Analytical sensitivity of FVM Ag rapid diagnostic test for malaria. Specimens for which parasite density had been verified by microscopic analysis were serially diluted with uninfected donor blood (10,000–150 parasites/μL for P. falciparum and 2,000–60 parasites/μL for P. vivax). The analytical sensitivity of
the FVM Ag RDT was compared with those of two commercial kits in Korea, namely, NanoSign™ Malaria Pf/Pan Ag (Bioland Ltd., Ochang, Republic of Korea) and BioLine™ Malaria Pf/Pan Ag (Standard Diagnostics Inc., Suwon, Republic of Korea). These kits detect HRP-II (T1) and pLDH (T2) to diagnose \( P. falciparum \) and pan malaria infections, respectively.

**Application of FVM Ag rapid diagnostic test for malaria to clinical samples and determination of test properties.** Two hundred nineteen malaria-positive blood samples (129 for \( P. vivax \), 86 for \( P. falciparum \), and 7 for \( P. vivax \) and \( P. falciparum \)) were obtained from the School of Medicine, Sungkyunkwan University (Suwon, Republic of Korea); School of Medicine, Inje University (Busan, Republic of Korea); Department of Laboratory Medicine, Ilsan Hospital (Goyang, Republic of Korea); and National Institute of Malariology, Parasitology and Entomology (Hanoi, Vietnam). Five hundred malaria-negative blood samples were kindly provided by the Cheongju Medical Center, Korean Hospital Association (Cheongju, Republic of Korea). All of these samples were examined and confirmed by using microscopic analysis and polymerase chain reaction, which amplified the \( Plasmodium \) circumsporozoite gene.28

To examine the parasite density, thick and thin blood smears were made immediately after blood collection and stained with 4% Giemsa for 20 minutes, and then analyzed by light microscopy in each laboratory. Parasites in thick blood films were counted against 200–500 leukocytes. Parasite density was estimated assuming 8,000 leukocytes/μL of blood. The sensitivity, specificity, and predictive values were calculated by using the formulas sensitivity = \( a/(a + c) \), specificity = \( d/(b + d) \), positive predictive value = \( a/(a + b) \), and negative predictive value = \( d/(c + d) \), where \( a \) is the number of true positive samples, \( b \) is the number of false-positives samples, \( c \) is the number of false-negative samples, and \( d \) is the number of true negative samples.

**Sequence alignment.** The ClustalW program (http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used to generate a pairwise sequence alignment of \( P/LDH \) (GenBank accession no. ABA46355) and \( P/vLDH \) (AAY59419).

**RESULTS**

**Properties of mAbs against \( Plasmodium \) LDH.** Although most of the hybridoma clones that we screened secreted antibodies that were cross-specific for \( P/LDH \) and \( P/vLDH \), we were able to identify 11 clones that produced antibodies with high affinities against pLDH (Table 1). Among them, four hybridoma clones (8C10, 5H11, 6G5, and 1G1) showed strong cross-reactivity with \( P/vLDH \) and \( P/LDH \). In addition, clones 8C10 and 5H11 had the highest mean (SD) affinities: \( K_d = 24.21 \) (2.07) nM and 12.03 (3.10) nM, respectively (Table 1). In addition, clone 8C10 had higher immunoreactivity with \( P/LDH \) and \( P/vLDH \). However, it did not exhibit any nonspecific reactions with malaria-negative blood samples (Figure 2). Conversely, clone 5H11 showed some nonspecific reactions with malaria-negative blood samples. As a result, we used clone 8C10 to produce the colloidal gold–conjugated mAb for our FVM Ag RDT.

Antibodies produced by hybridoma clones 2E11, 6E4, and 2H9 were \( P/LDH \) specific. Because antibody produced by clone 2E11 had the highest affinity and excellent specificity for \( P/LDH \) (Table 1 and Figure 2A), we used it as the \( P/LDH \)-specific capture antibody for T1 in our RDT. Similarly, antibodies produced by hybridoma clones 1H3, 3F3, 1E4, and 6E5 were \( P/vLDH \) specific. Because antibody produced by clone 1H3 had strongest immunoreactivity for \( P/vLDH \): mean (SD) \( K_d = 36.52 \) (1.12) nM, without cross-reacting with \( P/LDH \) (Figure 2A), we used it as the \( P/vLDH \)-specific capture antibody for T2 in our RDT.

**Table 1**

<table>
<thead>
<tr>
<th>Clone</th>
<th>Isotype</th>
<th>Immunogen</th>
<th>( K_d ) (nM)†</th>
<th>Immunogenicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>8C10</td>
<td>IgG1</td>
<td>( P/vLDH )</td>
<td>24.21 (2.07)</td>
<td>( PVLDH/P/LDH ) specific</td>
</tr>
<tr>
<td>5H11</td>
<td>IgG1</td>
<td>( P/LDH )</td>
<td>12.03 (3.10)</td>
<td>( PVLDH/P/LDH ) specific</td>
</tr>
<tr>
<td>1H3</td>
<td>IgG1</td>
<td>( P/vLDH )</td>
<td>36.52 (1.12)</td>
<td>( PVLDH ) specific</td>
</tr>
<tr>
<td>3F3</td>
<td>IgG2a</td>
<td>( P/LDH )</td>
<td>18.30 (1.03)</td>
<td>( PVLDH ) specific</td>
</tr>
<tr>
<td>1E4</td>
<td>IgG2a</td>
<td>( P/LDH )</td>
<td>541.1 (30.7)</td>
<td>( PVLDH ) specific</td>
</tr>
<tr>
<td>6E5</td>
<td>IgG2a</td>
<td>( P/LDH )</td>
<td>762.2 (50.1)</td>
<td>( PVLDH ) specific</td>
</tr>
<tr>
<td>6G5</td>
<td>IgG1</td>
<td>( P/LDH )</td>
<td>236.4 (11.0)</td>
<td>( PVLDH/P/LDH ) specific</td>
</tr>
<tr>
<td>1G1</td>
<td>IgG2b</td>
<td>( P/LDH )</td>
<td>142.4 (14.3)</td>
<td>( PVLDH/P/LDH ) specific</td>
</tr>
<tr>
<td>2E11</td>
<td>IgG1</td>
<td>( P/LDH )</td>
<td>25.24 (0.51)</td>
<td>( PVLDH ) specific</td>
</tr>
<tr>
<td>6E4</td>
<td>IgG1</td>
<td>( P/LDH )</td>
<td>28.33 (7.05)</td>
<td>( PVLDH ) specific</td>
</tr>
<tr>
<td>2H9</td>
<td>IgG1</td>
<td>( P/LDH )</td>
<td>421.1 (32.1)</td>
<td>( PVLDH ) specific</td>
</tr>
</tbody>
</table>

*†PVLDH, \( Plasmodium \) vivax lactate dehydrogenase; \( P/vLDH \, P. falciparum \) lactate dehydrogenase.

†The dissociation constant (\( K_d \)) was determined by using a Klotz plot, as described by Friquet and others. Values are mean (SD).

**Figure 2.** Immunoreactivity of monoclonal antibody (mAb) against \( Plasmodium vivax \) lactate dehydrogenase (LDH) (A) and \( P. falciparum \) LDH (B). Shown are hybridoma clones 2E11 (■), 8C10 (X), and 1H3 (Δ).
which are not always available in remote areas. In addition, variations in operator technique of preparing, staining, and interpreting blood films can produce different diagnoses.\textsuperscript{30,32} Moreover, in the case of samples with mixed-species infections, it is difficult to make a differential diagnosis by using microscopy. These shortcomings of using microscopy for malaria diagnosis motivated us to develop an improved and cost-effective RDT for on-site identification of mixed-species infections.

Unlike existing RDTs, which target two malaria antigens, our FVM Ag RDT targeted two similar antigens (\textit{Pf}LDH and \textit{Pv}LDH). Because the amino acid sequences of these two proteins are more than 90\% identical by pairwise sequence alignment, it was extremely difficult to develop specific mAbs. To overcome this difficulty, we used tagless \textit{Pv}LDH and \textit{Pf}LDH as immunogens to expose species-specific epitopes near their N-termini.

The targets of the two commercial RDTs that we compared in this study were \textit{Pf}HRP2 and pLDH. For the detection of \textit{P. falciparum}-positive samples, the difference in the detection limit of these RDTs was caused by one of the two targets. Although HRP2 provides better sensitivity than pLDH, it has problems with false-positive results because of its persistence in the circulatory system after parasite death.\textsuperscript{33,37} In this study, the detection threshold of our RDT for \textit{P. vivax}-positive samples was similar to that of NanoSign\textsuperscript{TM} Malaria \textit{Pf}/\textit{Pan} Ag but higher than that of BioLine Malaria \textit{Pf}/\textit{Pan} Ag. These results might be caused by the difference in immunoreactivity of the pLDH antigens. The analytical sensitivity of our RDT for \textit{P. falciparum} and \textit{P. vivax} was comparable with that of the commercial RDTs and is suitable for diagnostic applications, including on-site identification of mixed-species malaria.

Previous clinical studies have shown that the sensitivity of RDTs is generally 84–100\% for \textit{P. falciparum} and 75–96\% for \textit{P. vivax}, and the overall specificity is 75–96\%.\textsuperscript{30,36,38} For example, Ratsimbaoa and others\textsuperscript{39} reported that the sensitivity of various RDTs for \textit{P. falciparum} and \textit{P. vivax} were 97.0\% and 92.3\% for the CareStart Malaria Ag kit (AccessBio Inc., Monmouth Junction, NJ), 89.4\% and 73.3\% for the BioLine Malaria Ag (Standard Diagnostics Inc., Suwon, Republic of Korea), and 92.6\% and 86.7\% for the OptiMAL Malaria \textit{Pf}/\textit{Pv} Ag (DiaMed AG; Cressier sur Morat, Switzerland), respectively. Unlike these RDTs, which exhibited a lower sensitivity for \textit{P. vivax} than \textit{P. falciparum}, the sensitivity of our RDT was similar for both parasites (96.5\% for \textit{P. falciparum} and 95.3\% for \textit{P. vivax}). Collectively, these results showed that our FVM Ag RDT not only has superior sensitivity and specificity compared with existing RDTs but also the ability to differentiate \textit{P. falciparum}, \textit{P. vivax}, and mixed-species malaria infections.

To our knowledge, our FVM Ag kit is the first RDT with these capabilities. We anticipate that our RDT will be a useful diagnostic tool that will help improve the diagnosis and treatment of malaria, particularly in remote areas of the world.

Received April 27, 2011. Accepted for publication September 12, 2011.

Acknowledgments: We thank Stephanie K. Dalquist and Editage for editing the manuscript.

Authors’ addresses: Gyu-Cheol Lee, Research Team of Microbiology, Water Analysis and Research Center, Korea Institute of Water and Environment, K-water, 560 Sintanjin-ro, Daejeok-gu, Daejeon 306-711, Republic of Korea, E-mail: gclee@kwater.or.kr; Eun-Sung Jeon, Institute of BioMedicals, Bioland Ltd., 644-6 Gak-ri, Ochang, Jeonju, Republic of Korea, E-mail: asjon@kwater.or.kr; and Seungwhun Kim, Jeonju, Republic of Korea, E-mail: swkim@kwater.or.kr.
REFERENCES


4. Co EM, Dennull RA, Reinbold DD, Waters NC, Johnson JD. 2009. E-mails: hykim@chungbuk.ac.kr and ckchong01@hotmail.com. Natural Sciences, Chungbuk National University, 52 Naesudong-ro, 410-719, Republic of Korea, E-mail: jhyoo92@nhimc.or.kr. Hak Yong Kim, Department of Parasitology, School of Medicine, Inha University, Third Street, Sinheung-dong, Cheongin, Chungbuk 361-763, Republic of Korea, E-mails: hykim@chungbuk.ac.kr and ckchong01@hotmail.com.


